Product information and disease descriptionProduct descriptionProduct information
Contraindications/Warnings/Precautions/Adverse effects
29 evidence topics · 17 sources
Warnings and precautions
FDA-approved prescribing information for Barzolvolimab
Not applicable.
Adverse events through the Week 24 placebo-controlled period: pooled EMBARQ-CSU1 and EMBARQ-CSU2
“Pooled EMBARQ-CSU1 and EMBARQ-CSU2” (opens the source at this quote in a new tab)
“Rate of SAEs similar across treatment groups” (opens the source at this quote in a new tab)
| Adverse event, n (%) | Placebo Q4W | Barzolvolimab 150 mg Q4W | Barzolvolimab 300 mg Q8W |
|---|---|---|---|
| Participants (N) | “N=645” | “N=648” | “N=641” |
| Participants with at least 1 adverse event | “340 (52.7)” | “490 (75.6)” | “492 (76.8)” |
| Hair color changes | “29 (4.5)” | “292 (45.1)” | “330 (51.5)” |
| Skin hypopigmentation | “16 (2.5)” | “71 (11.0)” | “64 (10.0)” |
| Neutropenia | “4 (0.6)” | “59 (9.1)” | “75 (11.7)” |
| Skin hyperpigmentation | “5 (0.8)” | “59 (9.1)” | “58 (9.1)” |
| Dysgeusia | “9 (1.4)” | “44 (6.8)” | “63 (9.8)” |
| Hypogeusia | “10 (1.6)” | “33 (5.1)” | “53 (8.3)” |
| Nasopharyngitis | “36 (5.6)” | “41 (6.3)” | “40 (6.2)” |
| Anemia | “4 (0.6)” | “20 (3.1)” | “20 (3.1)” |
| Participants with serious adverse events | “15 (2.3)” | “6 (0.9)” | “14 (2.2)” |
| Treatment-related serious adverse events | “1 (0.2)” | “3 (0.5)” | “4 (0.6)” |
Anaphylaxis adjudication through the Week 24 placebo-controlled period: pooled EMBARQ-CSU1 and EMBARQ-CSU2
“G3 anaphylaxis adjudicated as unlikely” (opens the source at this quote in a new tab)
“G2 angioedema/throat tightness/urticaria” (opens the source at this quote in a new tab)
“G3 anemia/neutropenia;” (opens the source at this quote in a new tab)
“G2 malaise/dyspnea/chest pain;” (opens the source at this quote in a new tab)
“G3 anaphylaxis after placebo administration” (opens the source at this quote in a new tab)
Anaphylaxis adjudication: phase 2 in cold urticaria and symptomatic dermographism
Anaphylactic reaction: prurigo nodularis phase 1b, 3.0 mg/kg intravenous dose
Neutropenia and infection rates: phase 3
“Placebo: 23.9%” (opens the source at this quote in a new tab)
“150 mg Q4W: 24.4%” (opens the source at this quote in a new tab)
“300 mg Q8W: 23.6%” (opens the source at this quote in a new tab)
“Placebo: 0.6%” (opens the source at this quote in a new tab)
“150 mg Q4W: 9.1%” (opens the source at this quote in a new tab)
“300 mg Q8W: 11.7%” (opens the source at this quote in a new tab)
Hematologic laboratory decreases: phase 1b intravenous dosing in chronic spontaneous urticaria
“This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort (1: 0.5 mg/kg Q4W; 2: 1.5 mg/kg Q4W; 3: 3.0 mg/kg Q8W; and 4: 4.5 mg/kg Q8W) over 12 weeks” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Decreases in leukocytes, absolute neutrophil count, hemoglobin, and platelets were observed in patients after the first barzolvolimab dose when compared with placebo; no additional decreases were observed after subsequent doses (Figure S3). The majority of shifts were to Grades 1 and 2. A patient who received 4.5‐mg/kg barzolvolimab experienced a Grade 3 decrease in platelets; there was one patient also in the 4.5‐mg/kg group who experienced a Grade 2 decrease in WBC and did not receive the second dose per protocol; and three patients experienced Grade 3 decreased neutrophils (one in the 1.5‐mg/kg group and two in the 4.5‐mg/kg group); these all resolved during the study. There was no correlation of decreases with dose level. There were no trends of neutropenia correlating with increased infections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common AE related to treatment with barzolvolimab was mild hair color changes, followed by mild‐to‐moderate neutropenia, which was not associated with infections. Decreases in hematologic parameters were consistent with observations in healthy volunteers [10] and patients with chronic inducible urticaria [7] who received a single barzolvolimab dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hair color and skin pigmentation changes: phase 2 through Week 76
| Characteristic | Hair color changes | Skin hypopigmentation | Skin hyperpigmentation |
|---|---|---|---|
| Participants with the event | “n=49” | “n=36” | “n=6” |
| Grade 1, n (%) | “47 (96)” | “34 (94)” | “6 (100)” |
| Time to onset from start of barzolvolimab, days, mean (range) | “137 (7-397)” | “271 (107-424)” | “156 (11-283)” |
| Resolved at the time of data cutoff, n (%) | “40 (91)” | “19 (68)” | “4 (67)” |
| Time to resolution on treatment, days, median (95% CI) | “209 (119, 231)” | “110 (60, 120)” | “25 (7, NE)” |
| Time to resolution off treatment, days, median (95% CI) | “168 (138,189)” | “214 (196, 285)” | “NE” |
| Discontinued study treatment due to event, n (%) | “6 (3)” | “0 (0)” | “1 (<0.5)” |
Hair color changes: chronic inducible urticaria phase 1b
Taste changes: chronic inducible urticaria phase 1b
Taste changes: phase 1b in chronic spontaneous urticaria
“This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Taste changes, as noted in prior barzolvolimab studies, were reported by three patients (< 10%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Infections: phase 1b in chronic spontaneous urticaria
“This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 40% of barzolvolimab‐treated patients and 20% of placebo‐treated patients experienced an infection AE. The infections that were reported by > 10% of barzolvolimab‐treated patients were COVID‐19 (14%), nasopharyngitis (11%), and UTI (11%), and were not correlated with neutrophil decreases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment discontinuations for adverse events: phase 2 through Week 52
| Disposition, n (%) | Barzolvolimab 75 mg Q4W, then 150 mg or 300 mg | Barzolvolimab 150 mg Q4W | Barzolvolimab 300 mg Q8W | Placebo, then barzolvolimab 150 mg or 300 mg |
|---|---|---|---|---|
| Randomized | “n=53” | “n=52” | “n=52” | “n=51” |
| Discontinued treatment | “13 (25%)” | “13 (25%)” | “13 (25%)” | “8 (16%)” |
| Discontinued for an adverse event | “7 (13%)” | “4 (8%)” | “7 (13%)” | “2 (4%)” |
Reversibility off treatment: phase 2 follow-up to Week 76
Reversibility off treatment: chronic inducible urticaria phase 1b follow-up through Week 36
Phase 2 adverse events through Week 12
Phase 2 most common adverse events across doses
Phase 2 adverse events: placebo-controlled period to Week 16 and treatment period to Week 52
“Placebo Controlled Period (16 weeks)” (opens the source at this quote in a new tab)
“SAEs of worsening urticaria symptoms” (opens the source at this quote in a new tab)
“Adverse events were not dose dependent” (opens the source at this quote in a new tab)
| Participants, n (%) | Barzolvolimab, all doses, Weeks 0 to 16 | Placebo, Weeks 0 to 16 | Barzolvolimab, all doses, Weeks 0 to 52 | Placebo then barzolvolimab, 36 weeks of barzolvolimab |
|---|---|---|---|---|
| Participants (N) | “N= 156” | “N= 51” | “N= 156” | “N=48” |
| At least one adverse event | “103 (66)” | “20 (39)” | “139 (89)” | “32 (67)” |
| Treatment-related serious adverse events | “0” | “0” | “2 (1)” | “0” |
| Hair color changes | “22 (14)” | “0” | “40 (26)” | “8 (17)” |
| Neutropenia or neutrophil count decreased | “14 (9)” | “0” | “26 (17)” | “2 (4)” |
| Urticaria | “15 (10)” | “5 (10)” | “23 (15)” | “3 (6)” |
| Skin hypopigmentation | “2 (1)” | “0” | “21 (13)” | “9 (19)” |
| Nasopharyngitis | “6 (4)” | “3 (6)” | “15 (10)” | “4 (8)” |
Phase 1b adverse events at 24 weeks: intravenous dosing in chronic spontaneous urticaria
“This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort (1: 0.5 mg/kg Q4W; 2: 1.5 mg/kg Q4W; 3: 3.0 mg/kg Q8W; and 4: 4.5 mg/kg Q8W) over 12 weeks” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TEAEs reported by system organ class and preferred term in ≥ 10% barzolvolimab‐treated patients at 24 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment-emergent adverse event, n (%) | All barzolvolimab | Pooled placebo |
|---|---|---|
| Participants (N) | “N = 35”View highlighted excerpt for this quote | “N = 10”View highlighted excerpt for this quote |
| Any treatment-emergent adverse event | “30 (86)”View highlighted excerpt for this quote | “6 (60)”View highlighted excerpt for this quote |
| Neutropenia | “5 (14)”View highlighted excerpt for this quote | “0 (0)”View highlighted excerpt for this quote |
| Leukopenia | “3 (9)”View highlighted excerpt for this quote | “0 (0)”View highlighted excerpt for this quote |
| Headache | “5 (14)”View highlighted excerpt for this quote | “2 (20)”View highlighted excerpt for this quote |
| Hair color changes | “9 (26)”View highlighted excerpt for this quote | “0 (0)”View highlighted excerpt for this quote |
“Overall, 30 barzolvolimab‐treated patients (86%) and 6 placebo‐treated patients (60%) experienced a TEAE. In the 1.5‐mg/kg group, two barzolvolimab‐treated patients (6%) experienced infusion‐related TEAEs. One patient (3%) in the 3.0‐mg/kg group experienced a TEAE that led to drug interruption. No patients experienced a dose‐limiting toxicity or any TEAE that led to treatment discontinuation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hair color change was the most common event, experienced by nine barzolvolimab‐treated patients (26%; Table 2); hair color changes occurred in different locations: scalp, beard, and body hair; and seven patients had this TEAE resolve by the end of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most AEs were mild or moderate in severity and resolved while on study. One SAE of Grade 4 salmonella gastroenteritis in a 59‐year‐old Black woman (1.5‐mg/kg group) was assessed by the investigator as unrelated to study treatment; she was treated with Levaquin, was discharged, and completed the study as planned.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunogenicity: antidrug antibodies in phase 1b chronic spontaneous urticaria
“This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty‐seven percent (20/35) of patients were ADA positive, and the proportion of patients who experienced drug‐related AEs was similar in ADA‐positive and ADA‐negative patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment‐emergent ADA were observed in 57% of barzolvolimab‐treated patients, without apparent impact on exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Antibarzolvolimab antibodies did not appear to impact the safety parameters in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunogenicity: antidrug antibody status and exposure after a single intravenous dose in prurigo nodularis
Immunogenicity: risk factor text on antibodies against biologics
Chronic inducible urticaria phase 1b: single 3 mg/kg intravenous dose
Chronic inducible urticaria phase 2: Week 12 and Week 20 treatment periods
| Participants, n (%) | Barzolvolimab 150 mg Q4W | Barzolvolimab 300 mg Q8W | All barzolvolimab | Placebo |
|---|---|---|---|---|
| Participants (n) | “n=65” | “n=65” | “n=130” | “n=63” |
| Any adverse event | “40 (62%)” | “39 (60%)” | “79 (61%)” | “33 (52%)” |
| Treatment-related serious adverse events | “0” | “1 (2%)” | “1 (1%)” | “0” |
| Discontinued study treatment for adverse events | “1 (2%)” | “2 (3%)” | “3 (2%)” | “2 (3%)” |
| Hair color changes | “9 (14%)” | “8 (12%)” | “17 (13%)” | “0” |
| Neutropenia | “4 (6%)” | “9 (14%)” | “13 (10%)” | “0” |
Prurigo nodularis: adverse events after a single intravenous dose
Prurigo nodularis phase 2: 450 mg loading dose then 150 or 300 mg every 4 weeks
Eosinophilic esophagitis phase 2: 300 mg every 4 weeks through Week 44
Healthy volunteers: single intravenous doses of 0.3 to 9 mg/kg
“placebo‐controlled phase 1a healthy volunteer study of CDX‐0159” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A single dose of CDX‐0159 at 0.3, 1, 3, and 9 mg/kg, or placebo was intravenously administered to healthy subjects (Table 1). A CDX‐0159 intravenous infusion was well tolerated at all doses. The most common adverse event (AE)s observed in thirteen out of twenty‐four subjects who received CDX‐0159 were mild, self‐limited infusion reactions that were consistently described as areas of local itching associated with erythema, and induration/hives, which started during the infusions (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mild decreases in hemoglobin levels generally within the normal range were observed, which rapidly stabilized despite the presence of high plasma drug levels (Figure 3A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, all CDX‐0159 treatment groups showed variable, asymptomatic decreases relative to placebo on circulating neutrophils, which were also reflected in the total leukocyte count and did not further decline during the course of the study (Figure 3B,C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In our healthy volunteer study, there were no reports of hair color changes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment-emergent adverse event, n (%) | CDX-0159, all doses | Placebo |
|---|---|---|
| Participants (n) | “Total (n = 24)”View highlighted excerpt for this quote | “Placebo (n = 8)”View highlighted excerpt for this quote |
| Any event | “19 (79%)”View highlighted excerpt for this quote | “5 (63%)”View highlighted excerpt for this quote |
| Infusion-related reaction | “13 (54%)”View highlighted excerpt for this quote | “0 (0%)”View highlighted excerpt for this quote |
| White blood cell count decreased | “4 (17%)”View highlighted excerpt for this quote | “1 (13%)”View highlighted excerpt for this quote |
| Neutrophil count decreased | “4 (17%)”View highlighted excerpt for this quote | “1 (13%)”View highlighted excerpt for this quote |
| Sensation of foreign body in the throat | “3 (13%)”View highlighted excerpt for this quote | “0 (0%)”View highlighted excerpt for this quote |